Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Apellis Pharmaceuticals +2.47% Pre
Apellis Pharmaceuticals APLS | 27.34 27.34 | +2.47% 0.00% Pre |
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:
APLS) with a Outperform and maintains $100 price target.